{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:32:44Z","timestamp":1788535964976,"version":"build-2803163510"},"reference-count":69,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>Inhibition of NS5A has emerged as an attractive strategy to intervene in hepatitis C virus (HCV) replication. Ruzasvir (formerly MK-8408) was developed as a novel NS5A inhibitor to improve upon the potency and barrier to resistance of early compounds.<\/jats:p>","DOI":"10.1128\/aac.01280-18","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T12:59:15Z","timestamp":1535029155000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":6,"title":["<i>In Vitro<\/i>\n            Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A"],"prefix":"10.1128","volume":"62","author":[{"given":"Ernest","family":"Asante-Appiah","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Curry","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"McMonagle","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sony","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Department of In Vitro Pharmacology, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Carr","sequence":"additional","affiliation":[{"name":"Department of In Vitro Pharmacology, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rokosz","sequence":"additional","affiliation":[{"name":"Department of In Vitro Pharmacology, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4902-0435","authenticated-orcid":false,"given":"Frederick","family":"Lahser","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Bystol","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Chase","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Black","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ingravallo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wensheng","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kozlowski","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Merck &amp; Co., Inc., Kenilworth, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","unstructured":"WHO. 2017. Global hepatitis report 2017. World Health Organization Geneva Switzerland. http:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\/. Accessed 15 March 2018."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.23736\/S1121-421X.17.02448-5"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(16)01471-9"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2017.0136"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.006"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806104"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-015-0261-0"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1586\/17474124.2015.1111757"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2014.09.024"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2013.775246"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm100863x"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1240781"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.10.009"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2014.04.012"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.021"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.034801-0"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.000009"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.3390\/v7122968"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000177"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.09.011"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000319"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14478"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.01.007"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw336"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30073-8"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3253"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3177"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2016.06.063"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2016.01.050"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2016.08.097"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2016.07.057"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2016.06.056"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2016.05.041"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2016.04.084"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b01234"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2016.05.042"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2016.08.002"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b01310"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00363-17"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.3.540"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0753-x"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2016.1209484"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01390-15"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00051-16"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-017-0369-5"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1021\/ml300017p"},{"key":"e_1_3_3_48_2","volume-title":"Initial US approval","author":"AbbVie, Inc","year":"2014","unstructured":"AbbVie, Inc. 2014. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), co-packaged for oral use. Initial US approval. AbbVie, Inc, North Chicago, IL."},{"key":"e_1_3_3_49_2","volume-title":"Initial US approval","author":"AbbVie, Inc","year":"2015","unstructured":"AbbVie, Inc. 2015. Technivie (ombitasvir\/paritaprevir\/ritonavir), co-packaged for oral use. Initial US approval. AbbVie, Inc, North Chicago, IL."},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201300343"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00556-10"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24594"},{"key":"e_1_3_3_53_2","volume-title":"Prescribing information","author":"Gilead Sciences, Inc","year":"2015","unstructured":"Gilead Sciences, Inc. 2015. Harvoni (ledipasvir and sofosbuvir) tablets, for oral use. Prescribing information. Gilead Sciences, Inc, Foster City, CA."},{"key":"e_1_3_3_54_2","volume-title":"Zepatier (elbasvir and grazoprevir) tablets, for oral use, initial US approval","author":"Merck & Co, Inc","year":"2016","unstructured":"Merck & Co, Inc. 2016. Zepatier (elbasvir and grazoprevir) tablets, for oral use, initial US approval. Merck & Co, Inc, Kenilworth, NJ."},{"key":"e_1_3_3_55_2","volume-title":"Initial US approval","author":"Gilead Sciences, Inc","year":"2014","unstructured":"Gilead Sciences, Inc. 2014. Harvoni (ledipasvir and sofosbuvir) tablets, for oral use. Initial US approval. Gilead Sciences, Inc, Foster City, CA."},{"key":"e_1_3_3_56_2","volume-title":"Daklinza (daclatasvir) tablets, for oral use","author":"Bristol-Myers Squibb","year":"2015","unstructured":"Bristol-Myers Squibb. 2015. Daklinza (daclatasvir) tablets, for oral use. Initial US approval. Bristol-Myers Squibb, New York, NY."},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.972364"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2017.08.029"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30159-0"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28422"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00324-12"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2007.11.010"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.15.7904-7915.2004"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.290.5498.1972"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.09.023"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01256-12"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03534-14"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.10.056"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00527-13"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.3.1013-1020.2006"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01280-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01280-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:14:54Z","timestamp":1645478094000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01280-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":69,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1128\/AAC.01280-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.01280-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"2018-06-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01280-18"}}